Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UGT2B7 | P16662 | 1/20 | 0.62 |
| ▸ | MMP9 | P14780 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.45 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12871846 | 0.83 | UGT2B7 (0.61) | UGT2B7MMP9CYP2D6MEN1KMT2A | |
| SCHEMBL19286311 | 0.82 | UGT2B7 (0.59) | UGT2B7MMP9CYP2D6MEN1KMT2A | |
| SCHEMBL1320202 | 0.82 | UGT2B7 (0.59) | UGT2B7MMP9CYP2D6MEN1KMT2A | |
| SCHEMBL28276305 | 0.82 | UGT2B7 (0.59) | UGT2B7MMP9CYP2D6MEN1KMT2A | |
| SCHEMBL13804034 | 0.82 | UGT2B7 (0.59) | UGT2B7MMP9CYP2D6MEN1KMT2A | |
| SCHEMBL178531 | 0.82 | UGT2B7 (0.59) | UGT2B7MMP9CYP2D6MEN1KMT2A | |
| SCHEMBL30128757 | 0.80 | MMP9 (0.63) | UGT2B7MMP9CYP2D6MEN1KMT2A | |
| SCHEMBL15979349 | 0.80 | UGT2B7 (0.57) | UGT2B7MMP9CYP2D6MEN1KMT2A | |
| SCHEMBL2255110 | 0.80 | MMP9 (0.63) | UGT2B7MMP9CYP2D6MEN1KMT2A | |
| SCHEMBL23742756 | 0.80 | UGT2B7 (0.57) | UGT2B7MMP9CYP2D6MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210246122-A1 | Triazine Compounds and Uses Thereof | Aduro Biotech, Inc. (US) | 2021-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210246122-A1 | Triazine Compounds and Uses Thereof | IL5, IL15, TLR5 | UGT2B7 2389/4885MMP9 3671/4885CYP2D6 3022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.